WuXi Biologics and Vir Biotechnology Collaborate for the Global Development of Antibodies Against COVID-19

 WuXi Biologics and Vir Biotechnology Collaborate for the Global Development of Antibodies Against COVID-19

WuXi Biologics and Vir Biotechnology Collaborate for the Global Development of Antibodies Against COVID-19

Shots:

  • The companies will jointly develop, manufacture & commercialize Vir’s Ab. WuXi Biologics will conduct cell-line development, process & formulation development and initial manufacturing for clinical development
  • Following the regulatory approvals, Wuxi Biologics to get rights to commercialize therapies in Greater China while Vir retain WW commercial rights for the therapies
  • The collaboration accelerates the advancement of mAb against the global threat of COVID-19. Vir’s platform is used to identify rare Abs from survivor, treating rapidly evolving or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Wuxi Biologics

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post